Onesource Specialty Pharma Limited — Investor Meet, 12-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

OneSource Specialty Pharma reported Q1 FY26 revenue of INR 327.3 Cr (+12% YoY) and EBITDA of INR 88.5 Cr (+37% YoY), with margins up 500 bps. Management reiterated a muted H1, with strong H2 growth expected from Semaglutide commercial supplies. The DDC business shows robust momentum, with customer forecasts revised upwards and contracts secured by take-or-pay. Capacity expansion is accelerating, with 200M cartridge capacity by end CY26. The Board is evaluating potential acquisitions of Polish and Baroda facilities, expected to significantly boost revenues to over $500M by FY28, adding global footprint and injectable capabilities. The company maintains a confident outlook, backed by strong compliance and order book.